A genetically modified allogeneic cellular vaccine generates MHC class I-restricted cytotoxic responses against tumor-associated antigens and protects against CNS tumors in vivo

David M. Ashley, John H. Sampson, Gary E. Archer, Surinder K. Batra, Darell D. Bigner, Laura P. Hale

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

An active immunotherapeutic strategy using transfected allogeneic cells for targeting the mutant epidermal growth factor receptor (EGFRvIII) on intracranial tumors was examined. Immunization with allogeneic 300.19/EGFRvIII cells induced CD8+ cytotoxic T-lymphocytes against EGFRvIII bearing syngeneic B16-F10 melanoma or 560 astrocytoma cells (H-2(b)), but not against allogeneic NR6 cells (H-2(q)) also bearing EGFRvIII significant NK cell activity was also noted in vitro. Vaccination protected against intracranial challenge with EGFRvIII-positive tumor, with 50% long term survival. In vivo depletions of effector cell subsets demonstrated the requirements for both CD8+ and CD4+ T-cells but not NK cells in producing this protective effect. These data demonstrate the generation of significant, antigen-specific and MHC class I-restricted cytotoxic immune responses which are effective against tumors present in the CNS.

Original languageEnglish (US)
Pages (from-to)34-46
Number of pages13
JournalJournal of Neuroimmunology
Volume78
Issue number1-2
DOIs
StatePublished - Sep 1 1997

Fingerprint

Neoplasm Antigens
Vaccines
Neoplasms
Natural Killer Cells
Experimental Melanomas
Astrocytoma
Cytotoxic T-Lymphocytes
Epidermal Growth Factor Receptor
Immunization
Vaccination
epidermal growth factor receptor VIII
T-Lymphocytes
Antigens

Keywords

  • Antigen processing
  • Neuroimmunology
  • Rodent
  • Tumor immunity
  • Vaccination

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Neurology
  • Clinical Neurology

Cite this

A genetically modified allogeneic cellular vaccine generates MHC class I-restricted cytotoxic responses against tumor-associated antigens and protects against CNS tumors in vivo. / Ashley, David M.; Sampson, John H.; Archer, Gary E.; Batra, Surinder K.; Bigner, Darell D.; Hale, Laura P.

In: Journal of Neuroimmunology, Vol. 78, No. 1-2, 01.09.1997, p. 34-46.

Research output: Contribution to journalArticle

@article{93c6f5ed02344119afa68813fa9cb74d,
title = "A genetically modified allogeneic cellular vaccine generates MHC class I-restricted cytotoxic responses against tumor-associated antigens and protects against CNS tumors in vivo",
abstract = "An active immunotherapeutic strategy using transfected allogeneic cells for targeting the mutant epidermal growth factor receptor (EGFRvIII) on intracranial tumors was examined. Immunization with allogeneic 300.19/EGFRvIII cells induced CD8+ cytotoxic T-lymphocytes against EGFRvIII bearing syngeneic B16-F10 melanoma or 560 astrocytoma cells (H-2(b)), but not against allogeneic NR6 cells (H-2(q)) also bearing EGFRvIII significant NK cell activity was also noted in vitro. Vaccination protected against intracranial challenge with EGFRvIII-positive tumor, with 50{\%} long term survival. In vivo depletions of effector cell subsets demonstrated the requirements for both CD8+ and CD4+ T-cells but not NK cells in producing this protective effect. These data demonstrate the generation of significant, antigen-specific and MHC class I-restricted cytotoxic immune responses which are effective against tumors present in the CNS.",
keywords = "Antigen processing, Neuroimmunology, Rodent, Tumor immunity, Vaccination",
author = "Ashley, {David M.} and Sampson, {John H.} and Archer, {Gary E.} and Batra, {Surinder K.} and Bigner, {Darell D.} and Hale, {Laura P.}",
year = "1997",
month = "9",
day = "1",
doi = "10.1016/S0165-5728(97)00080-5",
language = "English (US)",
volume = "78",
pages = "34--46",
journal = "Journal of Neuroimmunology",
issn = "0165-5728",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - A genetically modified allogeneic cellular vaccine generates MHC class I-restricted cytotoxic responses against tumor-associated antigens and protects against CNS tumors in vivo

AU - Ashley, David M.

AU - Sampson, John H.

AU - Archer, Gary E.

AU - Batra, Surinder K.

AU - Bigner, Darell D.

AU - Hale, Laura P.

PY - 1997/9/1

Y1 - 1997/9/1

N2 - An active immunotherapeutic strategy using transfected allogeneic cells for targeting the mutant epidermal growth factor receptor (EGFRvIII) on intracranial tumors was examined. Immunization with allogeneic 300.19/EGFRvIII cells induced CD8+ cytotoxic T-lymphocytes against EGFRvIII bearing syngeneic B16-F10 melanoma or 560 astrocytoma cells (H-2(b)), but not against allogeneic NR6 cells (H-2(q)) also bearing EGFRvIII significant NK cell activity was also noted in vitro. Vaccination protected against intracranial challenge with EGFRvIII-positive tumor, with 50% long term survival. In vivo depletions of effector cell subsets demonstrated the requirements for both CD8+ and CD4+ T-cells but not NK cells in producing this protective effect. These data demonstrate the generation of significant, antigen-specific and MHC class I-restricted cytotoxic immune responses which are effective against tumors present in the CNS.

AB - An active immunotherapeutic strategy using transfected allogeneic cells for targeting the mutant epidermal growth factor receptor (EGFRvIII) on intracranial tumors was examined. Immunization with allogeneic 300.19/EGFRvIII cells induced CD8+ cytotoxic T-lymphocytes against EGFRvIII bearing syngeneic B16-F10 melanoma or 560 astrocytoma cells (H-2(b)), but not against allogeneic NR6 cells (H-2(q)) also bearing EGFRvIII significant NK cell activity was also noted in vitro. Vaccination protected against intracranial challenge with EGFRvIII-positive tumor, with 50% long term survival. In vivo depletions of effector cell subsets demonstrated the requirements for both CD8+ and CD4+ T-cells but not NK cells in producing this protective effect. These data demonstrate the generation of significant, antigen-specific and MHC class I-restricted cytotoxic immune responses which are effective against tumors present in the CNS.

KW - Antigen processing

KW - Neuroimmunology

KW - Rodent

KW - Tumor immunity

KW - Vaccination

UR - http://www.scopus.com/inward/record.url?scp=0030771380&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030771380&partnerID=8YFLogxK

U2 - 10.1016/S0165-5728(97)00080-5

DO - 10.1016/S0165-5728(97)00080-5

M3 - Article

C2 - 9307226

AN - SCOPUS:0030771380

VL - 78

SP - 34

EP - 46

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

SN - 0165-5728

IS - 1-2

ER -